What do systematic reviews say?

Proton pump inhibitors (PPI) vs H2RA, placebo or no treatment

Proton pump inhibitor treatment probably leads to lower endoscopic haemostatic treatment at index endoscopy compared with H2RA, placebo or no treatment (moderate certainty).

• Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding 2022 · Cochrane Headline outcomes only
  OR 0.68 [0.5, 0.93]
  3 studies · 1983 participants
  Moderate

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

Percutaneous endoscopic gastrostomy may leads to lower treatment failure Feeding interruption, blocking or leakage of the… compared with nasogastric tube feeding (low certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.18 [0.05, 0.59]
  8 studies · 408 participants
  Low

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

It is very uncertain whether percutaneous endoscopic gastrostomy changes mortality irrespective of compared with nasogastric tube feeding (very low certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.86 [0.58, 1.28]
  9 studies · 644 participants
  Very low

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

Percutaneous endoscopic gastrostomy showed no clear difference in pneumonia irrespective of compared with nasogastric tube feeding (low certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.7 [0.46, 1.06]
  7 studies · 645 participants
  Low

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

Percutaneous endoscopic gastrostomy showed no clear difference in adverse events irrespective of compared with nasogastric tube feeding (moderate certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.83 [0.51, 1.34]
  6 studies · 597 participants
  Moderate

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 240 participants
  Very low

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Biologics vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Low

Biologics vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 197 participants
  Very low

Cromolyn sodium vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found